Methicillin Resistant Staphylococcus Aureus Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Methicillin-Resistant Staphylococcus Aureus Drugs Market is Segmented by Drug Class (Oxazolidinones, Lipopeptides, Cephalosporin, Tetracycline, Folate Antagonist, Others), Route of Administration, Distribution Channel and Geography

Methicillin Resistant Staphylococcus Aureus Drugs Market Snapshot

Methicillin-Resistant Staphylococcus Aureus Drugs Market Overview
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: >3.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The methicillin-resistant Staphylococcus Aureus Drugs market is expected to register a growth at a CAGR of 3.6% during the forecast period.

The major factors attributing to the growth of the Methicillin-Resistant Staphylococcus Aureus (MRSA) drugs market are a rise in the global prevalence of MRSA infections, a rise in private and public funding for R&D of novel anti-MRSA drug molecules and their improved screening.

For instance, According to the CDC, 2% of the general population carries MRSA. Additionally, the increased practice of prescribing unnecessary and inappropriate antibiotics resulting in the rise of MRSA infections is likely to drive the growth of the global MRSA drug market.

Scope of the Report

As per the scope of the report, staphylococcus aureus is an important pathogen known to be associated with various forms of infections in humans, pets, and poultry. But over the decades, MRSA have become resistant to beta-lactam antibiotic called methicillin. In chickens, this pathogen is associated with several disease manifestations such as comb necrosis, lameness, and septicemia. Also, MRSA usually spreads in the community by contact with infected people or things that are carrying the bacteria, which fuels high demand to form effective treatment, and driving the market.

By Drug Class
Lipopeptides
Oxazolidinones
Cephalosporin
Tetracycline
Folate Antagonist
Others
By Route of administration
Oral Administration
Parenteral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Lipopeptide Segment is Expected to Hold the Largest Market Share in the Market

Lipopeptide segment accounts for the major market share owing to the novel antibiotic therapy introduced for MRSA. The therapy includes daptomycin, a lipopeptide class of drug and linezolid, an oxazolidinone class of antibiotics. The rapid implementation of therapy is expected to fuel the market growth. Furthermore, the glycopeptides and lipoglycopeptides segment is expected to show significant growth, owing to the increasing focus of manufacturers on the development of advanced drugs in this class.

Parenteral route of administration accounted for highest market share due to increased investment by pharmaceutical manufacturers to boost the production of intravenous anti-MRSA antibiotics.

methicillin resistant staphylococcus aureus drugs martket

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the overall MRSA drug market, throughout the forecast period. This dominance is mainly due to the investments by U.S. based companies in the R&D of screening tools for MRSA infection. Also, the rise in government support to treat MRSA lung infection in individuals with cystic fibrosis has fueled the market. For instance, in 2018, Cystic Fibrosis Foundation, at North American Cystic Fibrosis Conference announced that it will spend at least USD 100 million over the next five years to support improved detection, diagnosis, prevention, and treatment of infections related to cystic fibrosis.

Europe is the second most prominent region in the global MRSA drugs market, which is due to research grants by the public & private players in the European countries to propel the R&D of anti-MRSA antibiotics.

The Asia Pacific is set to grow at the fastest rate during the forecast period, driven by the huge patient pool in China and India, and the uncontrolled consumption of antibiotics in India is estimated to fuel the growth of the MRSA drugs market in the Asia Pacific.

Methicillin Resistant Staphylococcus Aureus Drugs Market - Growth Rate by Region

Competitive Landscape

The MRSA drug market is moderately competitive and consists of several prominent industry players. Some prominent players are acquiring blockbuster products in the market and expanding their market position. For instance, in 2018, Cumberland Pharmaceuticals Inc. acquired VIBATIV injection, an effective lipoglycopeptide class of drugs to treat MRSA, from Theravance Biopharma US, Inc. Whereas, other companies are making partnerships to consolidate their market leadership across the globe and while others are having new products in their pipeline. Some of the companies which are currently dominating the market are Melinta Therapeutics Inc., AbbVie Inc., Pfizer, Inc. Cumberland Pharmaceuticals Inc. and Merck & Co. Inc.

RECENT DEVELOPMENTS

  • In July 2021, Melinta Therapeutics announced the commercial launch of KIMYRSA, a lipoglycopeptide antibiotic that delivers a complete course of therapy for acute bacterial skin and skin structure infections. The U.S. Food and Drug Administration approved KIMYRSA on March 12, 2021, for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus
  • In January 2020, Wockhardt announced regulatory approval to two novel antibiotics EMROK (IV) and EMROK O (Oral), for acute bacterial skin and skin structure infections, including diabetic foot infections and concurrent bacteremia. The new drug will target superbug like Methicillin-resistant Staphylococcus aureus (MRSA), which is a leading cause of rising antimicrobial resistance

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increased Prevalence of Global Infections and Demand for Novel Therapies

      2. 4.2.2 Rise in Research Activities to Develop Novel MRSA Drugs by Key Players and Support by Government Initiatives

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Systematic Surveillance for MRSA Infection in Developing Countries

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Class

      1. 5.1.1 Lipopeptides

      2. 5.1.2 Oxazolidinones

      3. 5.1.3 Cephalosporin

      4. 5.1.4 Tetracycline

      5. 5.1.5 Folate Antagonist

      6. 5.1.6 Others

    2. 5.2 By Route of administration

      1. 5.2.1 Oral Administration

      2. 5.2.2 Parenteral

    3. 5.3 By Distribution Channel

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Retail Pharmacies

      3. 5.3.3 Online Pharmacies

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Cumberland Pharmaceuticals Inc

      2. 6.1.2 Pfizer Inc

      3. 6.1.3 AbbVie Inc.

      4. 6.1.4 Melinta Therapeutics Inc

      5. 6.1.5 Merck & Co Inc

      6. 6.1.6 Theravance Biopharma

      7. 6.1.7 Basilea Pharmaceutica

      8. 6.1.8 AmpliPhi Biosciences Corporation

      9. 6.1.9 Teva Pharmaceutical Industries ltd

      10. 6.1.10 Debiopharm International S.A.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Methicillin Resistant Staphylococcus Aureus Drugs Market market is studied from 2018 - 2026.

The Methicillin Resistant Staphylococcus Aureus Drugs Market is growing at a CAGR of >3.6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Pfizer Inc, Cumberland Pharmaceuticals Inc, Melinta Therapeutics Inc, Merck & Co Inc, AbbVie Inc. are the major companies operating in Methicillin Resistant Staphylococcus Aureus Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!